Related Experiment Video

Updated: Jun 1, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Molecular Validation of PACE4 as a Target in Prostate Cancer

François D'Anjou1, Sophie Routhier, Jean-Pierre Perreault

  • 1Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.

Translational Oncology
|June 3, 2011
PubMed

Insights

Prostate cancer research identifies PACE4 as a promising therapeutic target. Inhibiting PACE4 in prostate cancer cells slowed tumor growth and altered cancer-related gene expression, suggesting its crucial role in disease progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Prostate cancer is the most common cancer in men, with limited therapeutic options beyond androgen ablation.
  • Hormone-refractory prostate cancer develops after initial treatment, posing a significant clinical challenge.
  • Proprotein convertases (PCs) are implicated in cancer progression, but their specific role in prostate cancer requires further elucidation.

Purpose of the Study:

  • To investigate the expression of proprotein convertases (PCs) in prostate cancer.
  • To validate PACE4 as a potential therapeutic target for prostate cancer.
  • To understand the functional role of PACE4 in prostate cancer cell behavior and gene expression.

Main Methods:

  • Analysis of PACE4 expression in human prostate tumor tissues across various clinical stages.
  • Gene silencing of PACE4 in the DU145 prostate cancer cell line.
  • Assessment of cell proliferation, clonogenic activity, and xenograft growth in nude mice.
  • Gene expression and proteomic profiling of PACE4-silenced cells.

Main Results:

  • PACE4 was highly expressed in all stages of human prostate cancer tissues.
  • Silencing PACE4 in DU145 cells resulted in reduced proliferation, decreased clonogenic activity, and impaired xenograft formation.
  • Gene expression analysis revealed altered profiles of key cancer-related genes following PACE4 silencing.
  • Specific cancer-related genes (GJA1, CD44, IGFBP6) were upregulated, while others (MUC1, IL6) were downregulated in PACE4-silenced cells compared to controls.

Conclusions:

  • PACE4 is significantly upregulated in prostate cancer and plays a critical role in tumor progression.
  • Targeting PACE4 represents a promising therapeutic strategy for prostate cancer.
  • PACE4 likely influences prostate cancer progression through the modulation of growth factor processing.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...